missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Phospho-MYOD (Thr115) Polyclonal Antibody

Description
Antibody detects endogenous levels of MyoD1 only when phosphorylated at Thr115.
The Myogenic determination gene (MyoD) was first identified by the virtue of its ability to convert embryonic mouse fibroblast cells to muscle cells. It was subsequently shown that forced expression of MyoD (human homolog is myf 3) gene in a wide variety of normal and neoplastic cells could either convert the cells to muscle cells or activate a set of the otherwise transcriptionally inactive muscle-specific genes in these cells. The regulatory domain of the MyoD gene product lies within a 70 amino acid region and comprises a basic DNA binding motif and a helix-loop-helix (HLH) dimerization motif. Subsequent studies identified three other genes whose products shared sequence homology for the basic HLH domain of MyoD. These are; myf5, myogenin (human homolog is myf4) and myf6 (also known as MRF4 and herculin).
Specifications
Specifications
| Antigen | Phospho-MYOD (Thr115) |
| Applications | Immunohistochemistry (Paraffin), Western Blot, Immunocytochemistry |
| Classification | Polyclonal |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 50% glycerol and 0.02% sodium azide; pH 7.4 |
| Gene | MYOD1 |
| Gene Accession No. | P10085, P15172, Q02346 |
| Gene Alias | AI503393; bHLHc1; Class C basic helix-loop-helix protein 1; CMD1; MYF3; Myf-3; Myoblast determination protein 1; myoblast determination protein 1 homolog; Myod; MYOD1; Myod-1; MYOD1 homolog; myogenic differentiation 1; myogenic factor 1; myogenic factor 3; PUM; unnamed protein product |
| Gene Symbols | MYOD1 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?